Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre Sells 10,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $55.12, for a total value of $551,200.00. Following the completion of the transaction, the senior vice president now owns 168,176 shares of the company’s stock, valued at $9,269,861.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Halozyme Therapeutics Stock Performance

HALO opened at $56.23 on Friday. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. The business’s 50 day moving average is $50.02 and its 200-day moving average is $42.53. The stock has a market cap of $7.16 billion, a PE ratio of 23.24, a price-to-earnings-growth ratio of 0.56 and a beta of 1.27. Halozyme Therapeutics, Inc. has a twelve month low of $32.83 and a twelve month high of $57.08.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.07. The business had revenue of $195.88 million during the quarter, compared to the consensus estimate of $201.72 million. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. On average, analysts predict that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Benchmark lifted their target price on Halozyme Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. JMP Securities decreased their price objective on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a report on Wednesday, May 8th. Wells Fargo & Company increased their target price on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a report on Friday, June 7th. Piper Sandler lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $48.00 to $51.00 in a report on Friday, June 7th. Finally, The Goldman Sachs Group increased their price objective on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research note on Monday, July 22nd. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $58.38.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Rise Advisors LLC bought a new stake in Halozyme Therapeutics during the first quarter worth approximately $25,000. Whittier Trust Co. bought a new stake in shares of Halozyme Therapeutics in the 1st quarter worth $27,000. GAMMA Investing LLC raised its stake in shares of Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 254 shares in the last quarter. Principal Securities Inc. acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at $34,000. Finally, Fidelis Capital Partners LLC bought a new position in Halozyme Therapeutics during the first quarter valued at about $52,000. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.